App for #WCLC2024 downloaded and ready for virtual attendance. Here’s to a few days of learning about emerging research in #LungCancer On a more sobering note, I am remembering those EGFR+ friends I have made and lost along the way. Our work continues.

Interesting EGFR neoantigen therapy for EGFR+ NSCLC to overcome resistance presented at WCLC. New avenue which should be further explored! # MedIQWCLC24 #WCLC24

Excellent session highlighting that the UK is leading the way in early-phase trials combining drug-radiotherapy A standout example is the CONCORDE trial ➡️Platform trial incorporating multiple DDR inhibitors ➡️TITE-CRM Bayesian design ➡️Randomised controlled arm Leeds CTRU Cancer Research UK

Watch Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, Luis Paz-Ares, MD, PhD, & Joshua Sabari, MD (Joshua Sabari, MD) discuss the latest EGFR-MUTATED #NSCLC updates from #WCLC24 - to participate, visit: bit.ly/24EGFRLungT x.com/i/broadcasts/1…

#lungfluencer in the house representing YLCI at #WCLC2024 ! Leah Phillips 🤍🤍

The combination of tepotinib and osimertinib provided clinical benefit and had a manageable toxicity profile in patients with EGFR-mutated NSCLC whose disease progressed on frontline osimertinib and had MET amplification. Journal of Clinical Oncology #lcsm #oncology onclive.com/view/tepotinib…

IASLC global study on biomarker testing presented at #WCLC24 today by Dr. Smeltzer: ‘It’s no longer something nice to have, but a must for every #lungcancer pt.’ Wider access needed at all stages. Testing for mutations like #EGFR+ can be life-changing. ilcn.org/updated-biomar…

OA02.03 - Amivantamab/lazertinib vs. osi in 1st line EGFR+ advanced NSCLC: Longer f/u of MARIPOSA by Shirish Gadgeel - mOS: NE with ami/laz vs. 37.3 months with osi (HR 0.77) - 61% alive at 3 years with ami/laz vs. 53% with osi Important update from MARIPOSA #WCLC24

Dr. Se-Hoon Lee presents comparison between lazertinib and osimertinib in MARIPOSA (first-line #EGFR NSCLC) at #WCLC24. Not the primary analysis, which compared amivantamab + lazertinib vs osimertinib) but important for contribution of components.

Rilertinib: another 3rd Generation EGFr TKI at #WCLC24 OncoAlert

Who needs intensified therapy in the #EGFR-mt #NSCLC? Clx trials will inform these decisions but likely 🫁clinical features 🫁concomitant genomic alterations 🫁ctDNA+ IASLC #LCSM #wclc24

.@NarjusFlorezMD discusses taking into consideration patient preferences in choosing between the various options currently available for management of EGFR positive metastatic #NSCLC Oncology Brothers

Great discusison by Alfredo Addeo MD on #FURTHER Firmonertinib has clear activity against EGFR PACC. Note AEs (e.g. rash) that could impact QOL. Need more understanding of firmonertinib's activity on various compound PACC mutations (e.g. PACC-PACC, classical-PACC). #WCLC24

POLESTAR: Aumolertinib consolidation following Sequential or concurrent CRT. Treatment till PD/ tox. N=147. 85% x-over from control arm. HR PFS 0.2 Control arm median 3.8mo(!). ORR 57 vs22%. 15% increase in RT pneumonitis Supports LAURA but control arm poor performance #WCLC24

#WCLC24 Presidential II Superb discussion by Alfredo Addeo MD of FURTHER trial, next steps: 1. Response by compound PACC, single PACC, atypical mtns 2. Role of co-mtns 3. Monitor tox signal Congrats to authors- an important study, in an emerging subset of EGFR+ NSCLC IASLC #LCSM

The benefits of #research means that the #lungcancer treatment landscape is becoming more complex for clinicians and patients. Dr JessicaJLinMD walks us through how to consider some options for ALK, KRAS & EGFR in a review of several trials at #WCLC24 #ResearchSavesLives #LCSM

In this #WCLC24 episode, Narjust Florez, MD, FASCO discusses daily highlights. Xiuning Le MD PhD reports updated results of BAY 292708, & Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study. RadOncResearch adds her perspective of the POLESTAR trial evaluating EGFR therapy: bit.ly/WCLC24Mon

Big plans from our small but mighty charity! Chair Angela and Trustees Natasha, Gini & Soumitra met yesterday to talk projects, fundraising & raising awareness for #EGFR #LungCancer. A few surprise guests (we’ll spill soon!), and let’s just say… some BIG things are on the way!